-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 5, 2024

Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

Author(s)Derek van Amerongen, MD, MS, Soeren Mattke, MD, DSc, B. Joy Snider, MD, PhD

The panel provides insights on the economic impact of advanced approaches for diagnosing Alzheimer disease, highlighting how payers approach increased costs.

Episodes in this series

A panel of 5 experts on Alzheimer disease

EP. 1 The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS

EP. 2 Recent Insights into the Pathophysiology of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 3 Genetic Aspects of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 4 The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 5 Potential Consequences of Early Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 6 Criteria for Diagnosing Alzheimer Disease and the Role of Testing

A panel of experts on Alzheimer's disease

EP. 7 Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 8 Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 9 Clinical Decision-Making for Alzheimer Disease Management

A panel of experts on Alzheimer's disease

EP. 10 Cost, Value, and Affordability of Treatment for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 11 Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

A panel of 5 experts on Alzheimer disease

EP. 12 Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

A panel of 5 experts on Alzheimer disease

EP. 13 Payer Coverage Considerations for New Treatments for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 14 Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

Video content above is prompted by the following question(s):

What is the economic impact of more advanced diagnostic and monitoring techniques for Alzheimer disease?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

A study examines connections between obesity and DLBCL | Image: AdobeStock

Does BMI Have Prognostic Value in DLBCL? A Review Finds Mixed Results

July 10th 2026

4 Dice that spell out "FDA Approved" surrounded by pills on a table. | Image Credit: Frank H.-stock.adobe.com.jpeg

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

ByElla Hohmann, MS

July 10th 2026

Dr Jennifer Sheng | Image Credit: Johns Hopkins Medicine

Multidisciplinary Collaboration Advances Breast Cancer Care: Jennifer Sheng, MD

BySabrina McCrear,Jennifer Sheng, MD

July 10th 2026

Woman stands on the scales. Measuring tape. Weight loss - Atlas - stock.adobe.com

Setmelanotide Cuts BMI, Hunger in Phase 3 Trial for Hypothalamic Obesity

ByGiuliana Grossi

July 10th 2026

Stefanie Houseknecht, PharmD | Image Credit: LinkedIn

Pharmacists Help Navigate Precision Lung Cancer Care: Stefanie Houseknecht, PharmD

BySabrina McCrear,Stefanie Houseknecht, PharmD

July 10th 2026

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

AI Chatbots Score Below 28% on Colorectal Cancer Questions